← Back to Clinical Trials
Recruiting NCT06210100

NCT06210100 aiTBS for NSSI and Suicide in Adolescent Depression

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06210100
Status Recruiting
Phase
Sponsor Central South University
Condition Non Suicidal Self Injury
Study Type INTERVENTIONAL
Enrollment 60 participants
Start Date 2024-01-18
Primary Completion 2024-12-31

Trial Parameters

Condition Non Suicidal Self Injury
Sponsor Central South University
Study Type INTERVENTIONAL
Phase N/A
Enrollment 60
Sex ALL
Min Age 12 Years
Max Age 18 Years
Start Date 2024-01-18
Completion 2024-12-31
Interventions
Active iTBSSham iTBS

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Repetitive transcranial magnetic stimulation (rTMS) has been successfully used to help patients with treatment resistant depression. However, its role in alleviating self injuries with and without suicidal ideation remained uncertain. This trial will compare the effectiveness of active accelerated intermittent theta burst stimulation (aiTBS) rTMS to a placebo control on non-suicidal self injury (NSSI) and suicidal attempts in patients with major depressive disorder.

Eligibility Criteria

Inclusion Criteria: 1. Meet the DSM-5 (Diagnostic and Statistical Manual of Mental Disorders 5th Edition) diagnostic criteria for major depressive disorder. 2. Patients aged 12-18 years with at least one guardian to monitor them for 3 months 3. HAMD-17 Total score ≥18 4. Hospitalized patients who had two or more non-suicidal self-injury behaviors meeting the DSM-5 diagnostic criteria in the week before admission (NSSI behavior of more than 5 days in the past year, and a baseline DSHI score ≥2 ) 5. Obtain informed consent from patients and guardians Exclusion Criteria: 1. Substance abusers such as psychoactive drugs or alcohol. 2. Severe physical disability and unable to complete follow-up. 3. Comorbid other major mental illnesses that meet the DSM-5 criteria, such as bipolar disorder, schizophrenia, mental retardation, dementia, severe cognitive impairment, attention deficit hyperactivity disorder, etc. 4. Suffering from any severe physical disease, neurological disease, traumatic brai

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology